vTv Therapeutics Inc. VTVT
vTv Therapeutics Inc. (Nasdaq: VTVT) is a cardio-renal-metabolic drug developer. Its lead program, Cadisegliatin (TTP399), CATT1, is in Phase 3 for Adjunctive therapy to insulin in type 1 diabetes. Its next catalyst on record is Cadisegliatin, hybrid closed loop: Initiate Phase 2 study in T1D patients using hybrid closed loop systems (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Cadisegliatin, hybrid closed loop — Initiate Phase 2 study in T1D patients using hybrid closed loop systems (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Cadisegliatin, CATT1 | Type 1 diabetes (hypoglycemia outcomes) | small molecule | Phase 3 |
| Cadisegliatin (with G42 Investments) | Insulin-using type 2 diabetes, Middle East Phase 2 (300 patients) | small molecule | Phase 2 |
| Cadisegliatin with hybrid closed loop systems | Type 1 diabetes | small molecule | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.